Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Consumer Product Safety Commission

# AGENCY:

Consumer Product Safety Commission. 

# ACTION:

Notice of meeting.

# SUMMARY:

The Commission announces the third meeting of the Chronic Hazard Advisory Panel (CHAP) on phthalates and phthalate substitutes. The Commission appointed this CHAP to study the effects on children's health of all phthalates and phthalate alternatives as used in children's toys and child care articles, pursuant to section 108 of the Consumer Product Safety Improvement Act of 2008 (CPSIA) (Pub. L. 110-314). 

# DATES:

The meeting will be held Thursday,  December 2, and Friday, December 3, 2010. The meeting will begin at approximately 8 a.m. both days. It will end at approximately 5 p.m. on Thursday and approximately 3 p.m. on Friday. 

# ADDRESSES:

The meeting will be held in the fourth floor hearing room in the Commission's offices at 4330 East West Highway, Bethesda, Maryland. 

*Registration and Webcast:*                         Members of the public who wish to attend the meeting may register on the day of the meeting. This meeting will also be available live via Webcast December 2 and 3, 2010, at                         *http://www.cpsc.gov/​Webcast.*                         Registration is not necessary to view the Webcast. There will not be any opportunity for public participation at this meeting.                     

# FOR FURTHER INFORMATION CONTACT:

                        Michael Babich, Directorate for Health Sciences, Consumer Product Safety Commission, Bethesda, MD 20814; telephone (301) 504-7253; e-mail                         *mbabich@cpsc.gov.*

# SUPPLEMENTARY INFORMATION:

                    Section 108 of the CPSIA permanently prohibits the sale of any “children's toy or child care article” containing more than 0.1 percent of each of three specified phthalates: Di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), and benzyl butyl phthalate (BBP). Section 108 of the CPSIA also prohibits, on an interim basis, the sale of any “children's toy that can be placed in a child's mouth” or “child care article” containing more than 0.1 percent of each of three additional phthalates: diisononyl phthalate (DINP), diisodecyl phthalate (DIDP), and di-                    *n*                    -octyl phthalate (DnOP).                 

Moreover, section 108 of the CPSIA requires the Commission to convene a CHAP “to study the effects on children's health of all phthalates and phthalate alternatives as used in children's toys and child care articles.” The CPSIA requires the CHAP to complete an examination of the full range of phthalates that are used in products for children and: 
    - Examine all of the potential health effects (including endocrine disrupting effects) of the full range of phthalates;
    - Consider the potential health effects of each of these phthalates, both in isolation and in combination with other phthalates;
    - Examine the likely levels of children's, pregnant women's, and others' exposure to phthalates, based on a reasonable estimation of normal and foreseeable use and abuse of such products;
    - Consider the cumulative effect of total exposure to phthalates, both from children's products and from other sources, such as personal care products;
    - Review all relevant data, including the most recent, best-available, peer-reviewed, scientific studies of these phthalates and phthalate alternatives that employ objective data collection practices or employ other objective methods;
    - Consider the health effects of phthalates not only from ingestion but also as a result of dermal, hand-to-mouth, or other exposure;
    - Consider the level at which there is a reasonable certainty of no harm to children, pregnant women, or other susceptible individuals and their offspring, considering the best available science, and using sufficient safety factors to account for uncertainties regarding exposure and susceptibility of children, pregnant women, and other potentially susceptible individuals; and
    - Consider possible similar health effects of phthalate alternatives used in children's toys and child care articles.

                    The CHAP's examination must be conducted                     *de novo,*                     and the CPSIA contemplates completion of the CHAP's examination within 18 months of the CHAP's appointment. The CHAP must                           ( print page 73049)                        review prior work on phthalates by the Commission, but it is not to be considered determinative.                 

The CHAP must make recommendations to the Commission regarding any phthalates (or combinations of phthalates) in addition to those identified in section 108 of the CPSIA or phthalate alternatives that the panel determines should be prohibited from use in children's toys or child care articles or otherwise restricted. The CHAP members were selected by the Commission from scientists nominated by the National Academy of Sciences. See 15 U.S.C. 2077, 2030(b). 

The CHAP met previously on April 14-15, 2010, and July 26-28, 2010. The CHAP heard public comments at the July meeting. The December 2-3 meeting will include discussion of possible risk assessment approaches. The analysis of biomonitoring data will also be discussed. There will not be any opportunity for public comment at the December 2-3 meeting. 

Dated: November 19, 2010. 

Todd A. Stevenson, 

Secretary, Consumer Product Safety Commission.

[FR Doc. 2010-29868 Filed 11-26-10; 8:45 am] 

BILLING CODE 6355-01-P